MGMT gene silencing and benefit from temozolomide in glioblastoma.

By M. Hegi, A. Diserens, T. Gorlia, M. Hamou, N. Tribolet, Michael Weller, J. Kros, J. Hainfellner, W. Mason, L. Mariani and 6 more. New England Journal of Medicine, 2005

6,463 citations recorded by the source corpus.

Subfields: Genetics, Molecular Biology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/a3f84508219cc1dfb2987d60788aa33ebc6cd90e

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. S. Baylin
2. H. Ohgaki
3. P. Kleihues
4. Peter W. Laird
5. R. Jenkins
6. Guido Reifenberger
7. Eric S. Lander
8. E. Corrales-García

In Molecular Biology

1. S. Baylin
2. Peter W. Laird
3. Peter A. Jones
4. Eric S. Lander
5. Manel Esteller
6. Hui Shen
7. Jill P. Mesirov
8. Mauro Delorenzi

In Pulmonary and Respiratory Medicine

1. Ahmed Hosny
2. Hugo J. W. L. Aerts
3. Charles Swanton
4. H. Ohgaki
5. Matthew B. Schabath
6. P. Kleihues
7. M. Davis

Citations in the corpus

• Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. (2013, methodology): “A companion correlative subset study to the EORTC trial demonstrated a relationship between the tumor promoter region methylation status of the MGMT gene and outcome.(2) Tumor cells with high levels of MGMT protein are thought to be resistant to alklyating agents, and it would follow that successful”
• Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. (2015, background): “Duration of treatment with TTFields, median (range), mo 9 (1-58) 9 (1-58)”
• Mesenchymal Differentiation Mediated by NF-κB Promotes Radiation Resistance in Glioblastoma (2013, methodology): “…of the MES Signature, CD44, and NF-kB Signaling with Radiation Resistance Patients with GBM currently undergo standard treatment consisting of maximal surgical resection, combined radiation and chemotherapy, and adjuvant chemotherapy with temozolomide (Furnari et al., 2007; Hegi et al., 2005).”
• Epidemiologic and Molecular Prognostic Review of Glioblastoma (2014, methodology): “Additionally, it is associated with better response to TMZ as well as RT and improves progression free survival (PFS) and OS with combined treatment approach (TMZ + RT) than either treatment modality alone (77, 84, 92, 94, 95).”